ライフサイエンスコーパス: RSV

1 RSV A/GA2, A/GA5, and RSV B/BA were the most common geno

2 RSV binding to CX3CR1 contributes to disease pathogenesi

3 RSV can also cause severe complications in elderly and i

4 RSV coinfection with any respiratory virus is not associ

5 RSV entry blockers are in clinical trials, but escape mu

6 RSV F was expressed from the pre-N or N-P gene position

7 RSV fusion (F) glycoprotein is a key target for neutrali

8 RSV infection activates BRD4 acetyltransferase activity

9 RSV load measured by nasosorption (but not NPA) correlat

10 RSV LRTI accounted for 57% fatal LRTI tested for the vir

11 RSV type-A and B infections were most closely related to

12 RSV vaccine and antibody strategies are likely to be cos

13 RSV was the most frequent cause of mortality in low-inco

14 RSV-induced wheezing illnesses during infancy influence

15 had CRP >/=40 mg/L compared with 17% of 556 RSV pneumonia cases.

16 han 5 years who died with community-acquired RSV infection between Jan 1, 1995, and Oct 31, 2015, thr

17 In addition, RSV's importance as a largely unrecognized pathogen of d

18 Routine viral testing to estimate adult RSV disease burden has limitations.

19 results conclusively show that Chol affects RSV MA-membrane association by making the electrostatic

20 ess disease and pulmonary inflammation after RSV infection associated with reduced viral load.

21 g lymph nodes in wild-type BALB/c mice after RSV infection.

22 been shown to confer robust immunity against RSV infection in mice, cotton rats, and nonhuman primate

23 vaccine candidates that protect mice against RSV challenge.

24 be how F-specific antibodies protect against RSV and why specifically targeting prefusion F could hav

25 rotein to confer bivalent protection against RSV and HPIV3.

26 ite O binding and greater protection against RSV challenge.

27 antibodies and providing protection against RSV challenge.

28 genicity, and efficacy of protection against RSV challenge.

29 ild-type RSV and provided protection against RSV challenge.

30 antibodies play a role in protection against RSV infection in early life, but data regarding the conc

31 provided nearly complete protection against RSV infection in the upper and lower respiratory tract a

32 ta in H polygyrus-induced protection against RSV.

33 ed that nucleosides significantly alleviated RSV-induced replication stress and DNA damage response,

34 significant advance in the development of an RSV vaccine.

35 HMPV was detected in 7.3% (267 of 3650) and RSV in 28.7% (1048 of 3650).

36 ased life-threatening disease in RSV-ADV and RSV-influenza coinfection warrants further study.

37 RSV A/GA2, A/GA5, and RSV B/BA were the most common genotypes identified.

38 we find helices at the interfaces of HIV and RSV CA assemblies have very different contact angles, wh

39 Influenza and RSV were listed primary diagnoses in 56 (30%) vs 7 (6%),

40 sociated invasive pneumococcal serotypes and RSV detection during CAAP.

41 hways associated with timing of symptoms and RSV group (A/B).

42 treatment with the F(ab')2 form of the anti-RSV G 131-2G monoclonal antibody (MAb) show that mutatin

43 cy for RV-induced wheezing, whereas the anti-RSV mAb palivizumab decreases the risk of severe RSV-ind

44 the safety and efficacy of a live attenuated RSV vaccine.

45 clinical performance of the Aries Flu A/B & RSV assay was prospectively evaluated in comparison to t

46 al sensitivity values of the Aries Flu A/B & RSV assay were 98.1% for influenza A virus, 98.0% for in

47 ent of polymerase chain reaction (PCR)-based RSV testing and its impact on determining the seasonalit

48 We assessed antigen- and PCR-based RSV reports submitted to the National Respiratory and En

49 loped two parainfluenza virus 5 (PIV5)-based RSV vaccine candidates that protect mice against RSV cha

50 amined the genetic stability of a PIV5-based RSV vaccine in vitro and in vivo We found that insertion

51 molecular mechanisms of association between RSV MA and model membranes, and investigated how Chol en

52 delling suggests that cross-immunity between RSV, HMPV and human parainfluenzaviruses may contribute

53 /HPIV3 vector expressing RSV F as a bivalent RSV/HPIV3 vaccine and have been evaluating means to incr

54 All blocked RSV polymerase activity in minigenome assays.

55 The vaccines could also boost RSV neutralization antibody titers in African green monk

56 ion-stabilized RSV F mutant, or combine both RSV F and PIV5 backbone modifications.

57 ent viral entry and reduce disease caused by RSV.

58 piratory infections, 302 (5%) were caused by RSV.

59 Suppressing RSV infection by RSV immunoprophylaxis might increase the risk of having

60 Treg cell phenotype and function to control RSV infection.

61 However, a CPD RSV containing 1,378 synonymous mutations solely in the

62 spectives regarding evidence gaps in current RSV epidemiology in the United States, potential studies

63 Maternally derived RSV-specific antibodies play a role in protection agains

64 eeks during which antigen-based tests detect RSV in >10% of specimens (hereafter, the "10% threshold"

65 to assess the potential effect of different RSV immunisation strategies (targeting vaccination for i

66 LC3 responses in STAT1-deficient mice during RSV infection.

67 ansfected cells after the addition of either RSV-specific polyclonal antibodies (PAbs) or RSV glycopr

68 mice were infected intranasally with either RSV or UV-inactivated RSV.

69 This phase 2b study evaluated RSV postfusion F protein (120 microg) with glucopyranosy

70 y, a process through which surface-expressed RSV F proteins are internalized after interaction with R

71 virus 5 (PIV5)-vectored vaccines expressing RSV F (PIV5/F) or G (PIV5/G) protein in the cotton rat a

72 loping a chimeric rB/HPIV3 vector expressing RSV F as a bivalent RSV/HPIV3 vaccine and have been eval

73 developed previously as a vector expressing RSV fusion (F) protein to confer bivalent protection aga

74 ainfluenza virus 5 (PIV5) vectors expressing RSV glycoproteins for their immunogenicity and protectiv

75 ed with a nonlive, formalin-inactivated (FI)-RSV vaccine has been associated with serious enhanced re

76 FI-RSV-induced enhanced disease, observed in the 1960s, pre

77 compared to formaldehyde inactivated RSV (FI-RSV) and live RSV experimental infection.

78 to Pulmonary Infections and Asthma Following RSV Exposure [INSPIRE] study and the Tennessee Children'

79 For RSV, 287 (14.2%) patients were positive by RT-PCR and 23

80 For RSV, summary sensitivity was 75.3%, and specificity, 98.

81 45) or evaluated as outpatients (n = 20) for RSV infection, and healthy noninfected age-matched contr

82 , 98.0% for influenza B virus, and 97.7% for RSV.

83 cell responses is important to consider for RSV vaccines designed for young infants.

84 didates were generated in which the gene for RSV F was inserted into earlier positions in the PIV5 ge

85 from the pre-N position was immunogenic for RSV and HPIV1.

86 -based reports are increasingly relevant for RSV surveillance and determining the seasonality of RSV.

87 d bacterial pneumonia (sensitivity 77%) from RSV pneumonia (specificity 82%).

88 d local immunity and to protect animals from RSV challenge.

89 hospital admission rate, and mortality from RSV-ALRI episodes in young children in 2015.

90 d 966 differentially expressed proteins from RSV-infected cell supernatants were identified at a 1% f

91 VIII mAb, hRSV90, in complex with pre-fusion RSV F protein.

92 INTERPRETATION: Globally, RSV is a common cause of childhood ALRI and a major caus

93 irus (RSV)-associated LRTI, 1330 (57.3%) had RSV monoinfection, 38 (1.6%) had life-threatening diseas

94 The highest RSV neutralizing antibody responses were in the 30 micro

95 ymerase chain reaction (PCR) tests for HMPV, RSV, and 17 other pathogens.

96 of 11 patients and HCWs who had an identical RSV-B strain which was clearly distinct from strains rec

97 ting and discharge diagnoses for identifying RSV and influenza burden.

98 for pediatric clinical evaluation.IMPORTANCE RSV and HPIV3 are the first and second leading viral cau

99 s an intranasal pediatric vaccine.IMPORTANCE RSV and HPIV1 are major viral causes of acute pediatric

100 ion of inflammatory monocytes and T cells in RSV-challenged mice.

101 wever, increased life-threatening disease in RSV-ADV and RSV-influenza coinfection warrants further s

102 and interleukin 10 (IL-10) were elevated in RSV+ bronchiolitis (all P < .05), furthermore CCL5 and I

103 differentiation, stability, and function in RSV infection.

104 of HRV infection were significantly lower in RSV-infected infants in all cohorts, with adjusted odds

105 In vivo, mutations in RSV G and PIV5 L were found in individual isolates of PI

106 in the epithelial secretome participating in RSV lower respiratory tract infection-induced airway rem

107 also able to boost neutralization titers in RSV-preexposed African green monkeys.

108 e model compared to formaldehyde inactivated RSV (FI-RSV) and live RSV experimental infection.

109 animals immunized with formalin-inactivated RSV.

110 tranasally with either RSV or UV-inactivated RSV.

111 e and have been evaluating means to increase RSV F immunogenicity.

112 mmunogenic, eliciting complement-independent RSV-neutralizing antibodies and providing protection aga

113 sly developed vaccine candidate, we inserted RSV F at the PIV5 SH-HN gene junction or used RSV F to r

114 In contrast, full-length RSV F expressed from the pre-N position was immunogenic,

115 However, the vector expressing full-length RSV F from the pre-N position was immunogenic for RSV an

116 rmaldehyde inactivated RSV (FI-RSV) and live RSV experimental infection.

117 The RSV F glycoprotein is the major RSV neutralization antigen.

118 ical role of the p53-CXCR2 axis in mediating RSV-induced senescence.

119 ing antibody responses were in the 30 microg RSV-PreF/alum, 60 microg RSV-PreF/alum, and 60 microg RS

120 re in the 30 microg RSV-PreF/alum, 60 microg RSV-PreF/alum, and 60 microg RSV-PreF/nonadjuvant groups

121 alum, 60 microg RSV-PreF/alum, and 60 microg RSV-PreF/nonadjuvant groups.

122 ng mutations (DS-Cav1), and we also modified RSV F codon usage to have a lower CpG content and a high

123 Most RSV inpatients had pneumonia (84.1%), of whom 35% had se

124 cations to the PIV5 backbone, replace native RSV F with a prefusion-stabilized RSV F mutant, or combi

125 rus 5-vectored vaccine expressing the native RSV fusion protein (F) has previously been shown to conf

126 antibody responses established after natural RSV infections are poorly protective against reinfection

127 swabs and whole blood samples during natural RSV and rhinovirus (hRV) infection (acute versus early r

128 re underscore the need to evaluate a nonlive RSV vaccine candidate during preclinical development ove

129 oing obstacle for the development of nonlive RSV vaccine candidates.

130 el itself and to safe development of nonlive RSV vaccines for seronegative infants and children.

131 ses that included seroresponse to nonvaccine RSV antigens (VE, 8.9%; 90% CI, -28.5%-35.4%) or symptom

132 uenza (RR, 1.02; 95% CI, 1.01-1.02), but not RSV (RR, 0.99; 95% CI, .98-1.01), had a significant asso

133 Overall, 48.5% and 30.9% of RSV vaccine recipients reported local and systemic solic

134 nia virus of mice (PVM; a murine analogue of RSV).

135 antigen-antibody complexes after binding of RSV-specific antibodies to RSV antigens expressed on the

136 s provided more insights into the biology of RSV-induced stress and its cellular consequences.

137 egression analysis to estimate the burden of RSV in children younger than 5 years in England (UK), a

138 ide epidemiology and public health burden of RSV infection over time.

139 The burden of RSV is particularly great among outpatient children aged

140 dy viral interference, we evaluated cases of RSV and HRV codetection by polymerase chain reaction in

141 ed that we termed High Titre (HiT) clades of RSV.

142 Confirmation of RSV infection in the lower respiratory tract provides pr

143 bodies against the prefusion conformation of RSV F have more potent neutralizing activity than antibo

144 nd obtained nasal swabs for the detection of RSV during each respiratory illness.

145 ed as any day while alive after diagnosis of RSV infection during which </=2 L of supplemental oxygen

146 Immunization with optimal doses of RSV F antigens in the presence of GLA-SE induced high ti

147 The mean duration of RSV illness was longest (13.0 days) and the rate of pare

148 se data validate BRD4 as a major effector of RSV-induced inflammation and disease.

149 ncertainty range [UR] 21.6-50.3) episodes of RSV-ALRI, resulted in about 3.2 million (2.7-3.8) hospit

150 s remain about transmission and evolution of RSV in the community, between seasons, and the role play

151 no mutation that abolished the expression of RSV F or G.

152 The fusion glycoprotein (F) of RSV in either its postfusion (post-F) or prefusion (pre-

153 vector expressing a pre-F-stabilized form of RSV F demonstrated promising immunogenicity and should b

154 there are scarce data on the full impact of RSV infection on outpatient children.

155 ocol population (n = 1894), the incidence of RSV-associated ARI occurring >/=14 days after dosing was

156 group for severe pneumonia, independently of RSV infection.

157 rotein conformations, in vitro inhibition of RSV infection and propagation, and protective efficacy i

158 Nasosorption allowed measurement of RSV load and the mucosal inflammatory response in infant

159 TNF-alpha and/or MCP-1 in the mechanisms of RSV-induced exacerbation.

160 e titre was compared to the phylogenetics of RSV, emergent clades were identified that we termed High

161 ffect of interventions for the prevention of RSV disease.

162 The viral attachment protein of RSV has many surprising features, especially its mimicry

163 In search of RSV inhibitors, we have integrated a signature resistanc

164 its impact on determining the seasonality of RSV.

165 veillance and determining the seasonality of RSV.

166 Severity of RSV illness had the greatest effect size upon CD4 T-cell

167 BALB/c mice, 5C4 reduced the peak titers of RSV 1,000-fold more than 1129 did in both the upper and

168 be useful for the prevention or treatment of RSV infection and support the use of the pre-F protein a

169 products for the prevention and treatment of RSV infection.

170 The TMCT versions of RSV F were packaged in the rHPIV1 particles much more ef

171 the past 5 years, major research activity on RSV has yielded substantial new data from developing cou

172 6 months could have a substantial impact on RSV-related child mortality in low-income and middle-inc

173 Codon-optimized RSV F containing fewer CpG dinucleotides had higher F ex

174 RSV-specific polyclonal antibodies (PAbs) or RSV glycoprotein-specific monoclonal antibodies (MAbs),

175 ost tests detected only influenza viruses or RSV.

176 attractive antigen candidate for a pediatric RSV subunit vaccine.

177 PIV5-RSV F was equally protective when administered intranasa

178 the PIV5 genome [PIV5-RSV-F (HN-L) and PIV5-RSV-G (HN-L), respectively].

179 olymerase (L) genes of the PIV5 genome [PIV5-RSV-F (HN-L) and PIV5-RSV-G (HN-L), respectively].

180 The findings also that indicate PIV5-RSV F may be administered subcutaneously, which is the p

181 V5-RSV-G (HN-L), but plaque isolates of PIV5-RSV-F (HN-L) had no mutations.

182 L were found in individual isolates of PIV5-RSV-G (HN-L), but plaque isolates of PIV5-RSV-F (HN-L) h

183 To improve upon the PIV5-RSV-F (HN-L) candidate, additional vaccine candidates we

184 e of oil-in-water adjuvant) in a preclinical RSV susceptible cotton rat challenge model compared to f

185 There is no vaccine yet available to prevent RSV infection.

186 In addition, the VHHs prevent RSV replication and lung infiltration of inflammatory mo

187 ic site O are more efficacious at preventing RSV infection than antibodies specific for antigenic sit

188 ur data indicated that PIV5/F is a promising RSV vaccine candidate.IMPORTANCE A safe and efficacious

189 ne motif ((182)CWAIC(186)) in the G protein, RSV binds to the corresponding chemokine receptor, CX3CR

190 onferred complement-independent high-quality RSV-neutralizing antibodies at titers similar to those o

191 ent over a wide dose range in the cotton rat RSV enhanced-disease model, as suboptimal dosing of seve

192 ature resistance mutation into a recombinant RSV virus and applied the strain to high-throughput scre

193 wild type or mutant alone or in recombinant RSVs demonstrate that structural regions unique to NS1 c

194 Unanswered questions regarding RSV epidemiology need to be identified and addressed pri

195 RVs, RSV-B, and HCoV-OC43 infected ciliated cells and caused

196 sease model, as suboptimal dosing of several RSV F subunit vaccine candidates led to the priming for

197 culating CD4+ and CD8+ T cells during severe RSV infection of young children.

198 ophylaxis in neonates at high risk of severe RSV disease.

199 mAb palivizumab decreases the risk of severe RSV-induced illness and subsequent recurrent wheeze.

200 ace native RSV F with a prefusion-stabilized RSV F mutant, or combine both RSV F and PIV5 backbone mo

201 The vectors exhibited stable RSV F expression in vitro and in vivo In conclusion, an

202 ng the best available animal models to study RSV infection.

203 IFN-gamma or IL-27 significantly suppressed RSV-induced steroid-resistant airway hyperresponsiveness

204 Suppressing RSV infection by RSV immunoprophylaxis might increase th

205 shed up to Feb 3, 2015, using the key terms "RSV", "respiratory syncytial virus", or "respiratory syn

206 th a hospitalization rate 5 times lower than RSV.

207 n histone H3 Lys (K) 122, demonstrating that RSV infection activates BRD4 in vivo These data validate

208 We discovered that RSV infection induces a complex of bromodomain containin

209 There is definitive evidence that RSV-induced bronchiolitis can damage the airways to prom

210 between the different MAbs, indicating that RSV F internalization was epitope independent.

211 We observe that RSV induces BRD4 to complex with NF-kappaB/RelA.

212 Our study suggests that RSV infection is frequent in Laos and commonly associate

213 The RSV F glycoprotein is the major RSV neutralization antig

214 The RSV F protein and attachment (G) protein were found to b

215 The RSV fusion protein (F) is essential for virus entry beca

216 The RSV fusion protein (F) is highly conserved and is the on

217 hat insertions of foreign genes, such as the RSV F and G genes, were stably maintained in the PIV5 ge

218 ract illness (LRTI) were recorded during the RSV season.

219 PIV5 was engineered to express either the RSV fusion protein (F) or the RSV major attachment glyco

220 efect depth reduction (DDR) was found in the RSV group (30.80% +/- 8.35%, 41.86% +/- 6.76%) than in t

221 ssembly, the induction of curvature into the RSV CA hexamer lattice arises predominantly from reconfi

222 odifying the PIV5 vector or by modifying the RSV F antigen.

223 establish an atomic resolution model of the RSV CA tubular assembly using molecular dynamics flexibl

224 tigenic sites in the N- and C-termini of the RSV-G protein, that were boosted >10-fold by adjuvant an

225 ased quantitative proteomics analysis of the RSV-induced epithelial secretory response in cells repre

226 ess either the RSV fusion protein (F) or the RSV major attachment glycoprotein (G) between the hemagg

227 ross-reactive neutralizing antibodies to the RSV and HMPV fusion (F) proteins have been identified(10

228 The crystal structure of 5C4 bound to the RSV fusion (F) protein reveals that the overall binding

229 of serum immunoglobulin G antibodies to the RSV prefusion (pre-F), postfusion (post-F), and G glycop

230 after binding of RSV-specific antibodies to RSV antigens expressed on the surface of infected cells.

231 ed with more severe disease when compared to RSV alone in this study.

232 espiratory failure (RF) and mortality due to RSV were assessed using a hierarchical, logistic regress

233 cial, biologic, and clinical risk factors to RSV mortality in low-income regions is unclear.

234 need to be identified and addressed prior to RSV vaccine introduction to guide the measurement of imp

235 nd B infections were most closely related to RSV sequences from the USA and Asia, respectfully.

236 Inappropriate or dysregulated responses to RSV can be pathogenic, causing disease-enhancing inflamm

237 olymerase chain reaction [PCR]) compared to "RSV pneumonia" (nasopharyngeal/oropharyngeal or induced

238 8(+) T cell immunodominance hierarchy to two RSV-derived epitopes, K(d)M282-90 and D(b)M187-195, was

239 dies at titers similar to those of wild-type RSV and provided protection against RSV challenge.

240 ctive efficacy of recombinant unglycosylated RSV G protein ectodomain produced in E. coli (in presenc

241 SV F at the PIV5 SH-HN gene junction or used RSV F to replace PIV5 SH.

242 This provides an improved vectored RSV vaccine candidate suitable for pediatric clinical ev

243 Gag, as well as purified Rous sarcoma virus (RSV) MA and Gag, depends strongly on the presence of aci

244 oretroviruses, including Rous Sarcoma Virus (RSV), CA carries a short and hydrophobic spacer peptide

245 f influenza and respiratory syncytial virus (RSV) activity with risk of pulmonary exacerbation (PEx)

246 ivirals against respiratory syncytial virus (RSV) are being developed, but there are scarce data on t

247 ibodies against respiratory syncytial virus (RSV) are in development and likely to be available in th

248 d B viruses and respiratory syncytial virus (RSV) are three common viruses implicated in seasonal res

249 Respiratory syncytial virus (RSV) belongs to the family Paramyxoviridae and is the si

250 Data on how respiratory syncytial virus (RSV) genotypes influence disease severity and host immun

251 seasonality of respiratory syncytial virus (RSV) has traditionally been defined on the basis of week

252 icant burden of Respiratory Syncytial Virus (RSV) in pediatric and elderly populations is well recogn

253 However, both respiratory syncytial virus (RSV) infection and mutations in the receptor for advance

254 es polygyrus on respiratory syncytial virus (RSV) infection in a mouse model.

255 Respiratory syncytial virus (RSV) infection induces asthma exacerbations, which leads

256 Respiratory syncytial virus (RSV) infection is an important cause of pneumonia mortal

257 Respiratory syncytial virus (RSV) infection of children previously immunized with a n

258 ed on APC after respiratory syncytial virus (RSV) infection, and its inhibition leads to exaggerated

259 hybrid model of respiratory syncytial virus (RSV) infection, we previously demonstrated that the CD8(

260 in response to respiratory syncytial virus (RSV) infection.

261 MPORTANCE Human respiratory syncytial virus (RSV) is a global leading cause of infant mortality and a

262 Respiratory syncytial virus (RSV) is an exceptional mucosal pathogen.

263 Respiratory syncytial virus (RSV) is an important cause of illness in older adults.

264 The Human respiratory syncytial virus (RSV) is one of the most important viral pathogens, causi

265 research, human respiratory syncytial virus (RSV) is still a major health concern for which there is

266 Human respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract inf

267 Human respiratory syncytial virus (RSV) is the leading cause of pediatric bronchiolitis and

268 Respiratory syncytial virus (RSV) is the most common cause of viral acute lower respi

269 Respiratory syncytial virus (RSV) is the most important viral agent of severe pediatr

270 Human respiratory syncytial virus (RSV) is the most prevalent worldwide cause of severe res

271 sed vaccine for respiratory syncytial virus (RSV) is unavailable, and passive prophylaxis with the an

272 Respiratory syncytial virus (RSV) lower respiratory tract infection is implicated in

273 Respiratory syncytial virus (RSV) remains a major human pathogen, infecting the major

274 ovirus (RV) and respiratory syncytial virus (RSV) replication.

275 Respiratory syncytial virus (RSV) represents a threat to infants, the elderly, and th

276 and efficacious respiratory syncytial virus (RSV) vaccine remains elusive.

277 estimated that respiratory syncytial virus (RSV) was associated with 22% of all episodes of (severe)

278 e infected with respiratory syncytial virus (RSV) within the first 2 years of life, with a minority d

279 viruses, 32 for respiratory syncytial virus (RSV), and 13 for other respiratory viruses.

280 uding that from respiratory syncytial virus (RSV), has been previously associated with the developmen

281 main target of respiratory syncytial virus (RSV), it also infects immune cells, such as macrophages

282 d children with respiratory syncytial virus (RSV)-associated LRTI, 1330 (57.3%) had RSV monoinfection

283 es for HMPV and respiratory syncytial virus (RSV).

284 enza virus, and respiratory syncytial virus (RSV).

285 t samples, 24.5% (798) and 37.3% (1216) were RSV and HRV positive, respectively.

286 nza activity in children and adults and with RSV activity in children.

287 mmune cell phenotypes may be associated with RSV clinical severity.

288 ial pneumonia and negatively associated with RSV pneumonia in PERCH.

289 was highest (136 days per 100 children with RSV illness) in children aged <3 years.

290 A substantial proportion of children with RSV-related death had comorbidities.

291 We studied 358 children with RSV-related in-hospital death from 23 countries across t

292 , furthermore CCL5 and IL-10 correlated with RSV load (P < .05).

293 sample of healthy infants hospitalized with RSV bronchiolitis.

294 developed a severity score for infants with RSV infection that should be useful as an end point for

295 Infants infected with RSV representing extremes of clinical severity were stud

296 d by HSV-2 and in vivo in mice infected with RSV.

297 infants with severe LRTI were infected with RSV.

298 eins are internalized after interaction with RSV-specific antibodies is described.

299 mber of admissions to hospital occurred with RSV compared with influenza.

300 ular senescence in cancer cells treated with RSV.